Clinical trial · Observational
The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression
The Gene Expression Studies of Tumor Microenvironments and Their Roles in Tumor Progression
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): the study has stopped due to no recruitment
Summary
Brief summary (as posted)
The purpose of this study is to analyze the gene expression patterns associated with various microenvironmental stresses in tumors to understand their roles in tumor progression and treatment responses. To achieve this goal, we will perform gene expression analysis of the tumor samples collected from an IRB-approved study (IRB #: 4516-05-2R2) International Phase III Study of Chemoradiotherapy versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer directed by Dr. Mark Dewhirst. We will correlate the gene expression signatures of different microenvironmental stresses with the measured physiological parameters to understand their role in tumor progression, treatment response and clinical outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hypoxia | — | UNRESOLVED | — |
| Lactic Acidosis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- The purpose of this study is to analyze the gene expression patterns associated with various microenvironmental stresses in tumors to understand their roles in tumor progression and treatment responses. To achieve this goal, we will perform gene expression analysis of the tumor samples collected from an IRB-approved study (IRB #: 4516-05-2R2) International Phase III Study of Chemoradiotherapy versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer directed by Dr. Mark Dewhirst. We will correlate the gene expression signatures of different microenvironmental stresses with the measured physiological parameters to understand their role in tumor progression, treatment response and clinical outcomes.
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Invasive cervical carcinoma (small cell histology excluded) * Age 18 or over * FIGO stage IIb-IVa * ECOG/WHO 0,1, or 2, or \>/= 70% respectively * WBC \>/= 3,000, platelets \>/= 100,000 * Hgb\>12.0 g/dL or \>7.5 mmol/L, with transfusion if needed * Serum bilirubin \</= 1.5 times ULN, transaminase \</= 3 times ULN * Calculated creatinine clearance \> 60 ml/liter (Cockcroft) * Para-aortic adenopathy absent or 1.5 cm in greatest dimension on CT/MRI * No history of myocardial infarction in the last 6 months * No symptomatic angina pectoris * Any past history of coronary artery disease must require assessment and clearance by the PCP and/or cardiologist * Negative pregnancy test in patients under 50 * Written informed consent Exclusion Criteria: * Patients who have undergone surgical resection of the primary tumor are not eligible (Limited surgical resection of pelvic nodes without TAH is acceptable) * Patients with pacemakers or implanted defibrillators * Patients with significant metallic foreign bodies (i.e. hip replacements, bone metallic rods, orthopedic plates, etc.) * Prior radiotherapy or chemotherapy
References
Publications (0)
Data not yet available